What FDA's Warning Letters Say About 'Research Use Only' Peptides

What happened / Why it matters

What happened. In letters dated Aug. 24, 2026, FDA’s drug center (CDER) warned three online peptide sellers: NuScience Peptides, LLC; TXP Innovations, LLC, doing business as Tex Peptides; and Royal Peptides, LLC. FDA said that products sold with labels such as “research use only” are, based on evidence on the companies’ own websites, intended for human use, and are therefore unapproved new drugs.

Why it matters. A “for research use only” or “not for human consumption” label can look like a legal category. In these letters, FDA says the label did not change its conclusion. This analysis explains what FDA cited and what a warning letter does and does not establish. It states FDA’s position as of the letters’ dates. It is not a court ruling.

What did FDA say about the “research use only” label?

Each letter contains the same core statement, with the quoted labels differing by company. In the NuScience letter, FDA wrote that “despite statements on your product labeling marketing your products ‘for laboratory, research, and analytical use’ and ‘not intended for human or veterinary use,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.” The Tex Peptides letter quotes “research use only” and “not for human or veterinary use” labels, and the Royal Peptides letter quotes “for research use only” and “not for human or animal consumption,” and reaches the same conclusion.

FDA’s reasoning rests on “intended use,” a concept in its regulations. The letters say a product is a drug if it is intended to diagnose, cure, treat or prevent disease, or to affect the structure or function of the body, and they cite examples “from your product labeling, including on your website,” as evidence of intended use.

What evidence did FDA cite?

FDA reviewed the companies’ websites in July 2026. According to the letters (NuScience, Tex, Royal), the evidence included:

• Descriptions of effects. FDA quoted passages from the websites about weight loss, blood sugar control, appetite, libido and other effects, including some framed as research, and in one case a description of a product as a “valuable therapeutic candidate.” The quoted text appears in the letters; we do not reproduce it here.
• Comparisons of weight-loss results. The Royal Peptides letter quotes web pages comparing products by clinical weight-loss results.
• Bacteriostatic water sold alongside the peptides. In the NuScience and Tex letters, FDA said the sale of water to reconstitute injectable peptides together with the peptides shows an intent that the water be used for injection, so it treated the water as a drug too.
• Tools for preparing an injection. FDA said the NuScience and Royal sites marketed water alongside a “peptide calculator” (and, for Royal, a “peptide guide”), which it described as resources that provide “the means to prepare an injectable drug for human administration.” FDA said the Tex site marketed bacteriostatic water as a solvent for reconstituting its products, which also provides that means. We do not describe how such preparation works.

Which products did FDA name?

The three letters (NuScience, Tex, Royal) cover different product lists. All three name products containing semaglutide, tirzepatide and retatrutide, as well as tesamorelin and PT-141 (bremelanotide). The NuScience and Tex letters also name bacteriostatic water as a drug. The NuScience letter also names survodutide and mazdutide. The Tex and Royal letters also name SS-31 (elamipretide). The NuScience and Royal letters also name a blend of tesamorelin and ipamorelin.

FDA’s conclusion is about each company’s product, which it says has no approved application. It is not a statement that semaglutide, tirzepatide, tesamorelin or bremelanotide as medicines are unapproved. Some of these molecules are in FDA-approved products made by other companies, such as Wegovy (semaglutide), Zepbound (tirzepatide), Egrifta WR (tesamorelin) and Vyleesi (bremelanotide). That is a separate matter.

Why is the label not what it seems?

Based on these letters:

• FDA did not treat the label as decisive. In these letters, FDA cites website statements and the sale of water and preparation tools as evidence that the products are intended for human use, despite the disclaimers.
• No approved application. FDA said in the letters that no approved application is in effect for the products. FDA’s page on unapproved GLP-1 drugs says products of this kind are “of unknown quality and may be harmful,” and that FDA has warned companies selling unapproved drugs that are falsely labeled “for research purposes” or “not for human consumption.”
• Injectables raise the stakes. The letters say injectable drugs “can pose risks of serious harm to users” because they bypass some of the body’s defenses against toxins and microorganisms.
• It is a different channel from compounding. A compounded drug is made by a licensed pharmacist or physician for an individual patient under a prescription. The letters concern sellers of products labeled for research. HHS’s Oct. 30 interim policy says its aim is to steer patients away from “research-use-only peptides supplied by foreign manufacturers.” It names state-licensed pharmacies, federal facilities and licensed physicians. As we read it, it does not extend to web sellers. None of the products named in these letters is in its Appendix A. It is not FDA approval.

What does a warning letter not prove?

• It is not a ruling. A warning letter states FDA’s findings and position on the facts it reviewed. Each letter gave the company 15 business days to respond and invited it to submit information showing its products were not in violation. We have not checked any response or later action.
• It is not a finding about product quality. The letters concern website claims and marketing, not lab testing of the products.
• It is not a full list of violations or of sellers. The letters say they are “not intended to be an all-inclusive list of the violations.” They name three companies, not the market.
• It does not say what any buyer did. The letters concern sellers.
• A warning about seizure is not a seizure. The letters say failure to address violations “may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.” That is a warning, not an action taken.

What does this mean for a reader?

• “Research use only” on a product sold with claims about its effects and the means to inject it is not, in FDA’s view, a sign of legality or quality.
• Anyone considering a treatment for weight, sexual health or any other condition can talk with a licensed clinician about approved options.
• Anyone who has had a serious reaction to a product can report it to FDA’s MedWatch program.
• We do not link to these sellers, and we do not provide dosing, preparation or purchasing guidance.

U.S. regulatory status checked Oct. 31, 2026. This article reports FDA’s positions in letters dated Aug. 24, 2026; we have not checked the companies’ responses or any later FDA action.